Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond.
Lung Cancer
; 156: 147-150, 2021 06.
Article
in En
| MEDLINE
| ID: mdl-33965281
Full text:
1
Database:
MEDLINE
Main subject:
COVID-19
/
Lung Neoplasms
Type of study:
Observational_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Lung Cancer
Journal subject:
NEOPLASIAS
Year:
2021
Type:
Article
Affiliation country:
United kingdom